Milestone Pharmaceuticals (MIST) said Wednesday it received notice of allowance from the US Patent and Trademark Office on a patent for etripamil nasal spray, the company's investigational product to manage paroxysmal supraventricular tachycardia.

The patent covers the repeat dose regimen used in a phase 3 study that assessed the nasal spray in paroxysmal supraventricular tachycardia and was proposed for the package insert as part of the nasal spray's new drug application that is under review by the US Food and Drug Administration, the company said.

The repeat dose regimen directs the patient to take a second 70-milligram dose of the nasal spray if the person is still seeing symptoms from their paroxysmal supraventricular tachycardia episode 10 minutes after the initial dose, Milestone said.

The issuance of the notice of allowance potentially extends the company's intellectual property protection for the nasal spray in the US until July 2042, Milestone said.

The company said it's still advancing commercial preparations to back the expected launch of the nasal spray, with the brand name Cardamyst, in mid-2025.

Price: 2.20, Change: -0.01, Percent Change: -0.45